Results presented here demonstrate that mTORC1 inhibition with PRAS40 prevents the development of diabetic cardiomyopathy and improves hepatic insulin sensitivity, revealing a new target for treatment of T2DM and associated cardiomyopathy. This evidence concerns the gene AKT1S1 and type 2 diabetes mellitus.